BDBM413654 4-[(2-{4-[5-Chloro-2-(1,2-oxazol-3-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}-3-[(2S)-tetrahydro-2H-pyran-2-yl]propanoyl)amino]benzoic acid (Diastereomer Mixture)::US10421742, Example 48::US10421742, Example 49::US11180471, Example 49

SMILES COc1cn(C(C[C@@H]2CCCCO2)C(=O)Nc2ccc(cc2)C(O)=O)c(=O)cc1-c1cc(Cl)ccc1-c1ccon1

InChI Key InChIKey=RTTPBBKILQCFGH-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 413654   

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(US10421742, Example 48 | 4-[(2-{4-[5-Chloro-2-(1,2...)
Affinity DataIC50: 1nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(US10421742, Example 48 | 4-[(2-{4-[5-Chloro-2-(1,2...)
Affinity DataIC50: 0.360nMAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(US10421742, Example 48 | 4-[(2-{4-[5-Chloro-2-(1,2...)
Affinity DataIC50: 49nMAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(US10421742, Example 48 | 4-[(2-{4-[5-Chloro-2-(1,2...)
Affinity DataIC50: 17nMAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2020
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(US10421742, Example 48 | 4-[(2-{4-[5-Chloro-2-(1,2...)
Affinity DataIC50: 1nMAssay Description:FXIa: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting fin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(US10421742, Example 48 | 4-[(2-{4-[5-Chloro-2-(1,2...)
Affinity DataIC50: 0.360nMAssay Description:FXIa: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting fin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(US10421742, Example 48 | 4-[(2-{4-[5-Chloro-2-(1,2...)
Affinity DataIC50: 49nMAssay Description:Plasma Kallikrein: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413654(US10421742, Example 48 | 4-[(2-{4-[5-Chloro-2-(1,2...)
Affinity DataIC50: 17nMAssay Description:Plasma Kallikrein: Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent